Shield Therapeutics to Attend BIO-Europe® 2013
LONDON, October 23, 2013 /PRNewswire/ --
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that Richard Jones, Chief Financial Officer, and Angela Hildreth, Group Financial Controller, will attend BIO-Europe®2013 which takes place on Monday 4th to Wednesday 6th November in Vienna, Austria.
If you would like to arrange a meeting with a representative of Shield Therapeutics, please request a meeting via the conference partnering system. Alternatively, you can request a meeting by visiting the contact us page on Shield Therapeutics website http://www.shieldtherapeutics.com.
About Shield Therapeutics
Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently conducting pivotal Phase 3 studies of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.
For more information about Shield Therapeutics, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson/ Lindsey Neville
Tel +44(0)20-7920-2333
E-mail: shieldtherapeutics@mcomgroup.com
Share this article